ELIGARD 7.5mg: may not be filled with correct amount of leuprolide acetate.
Last updated
Summary
Product
ELIGARD 7.5mg
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Distribution
Alberta
British Columbia
Ontario
Quebec
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
ELIGARD |
ELIGARD 7.5mg 1-month |
DIN 02248239 |
Powder for Suspension |
7.5mg Leuprolide acetate for injection |
13635C1 |
Issue
| Affected lot may not be filled with the correct amount of leuprolide acetate. |
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers
Details
Original published date: 2023-09-12
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Recalling firm:
|
Tolmar Inc. 701 Centre Ave., Fort Collins, CO, USA, 80526 Canadian Legal Contact: Innomar Strategies Inc. 8030 Esquesing Line, Unit B, Milton, ON, L9T 6WC
|
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
Alberta
British Columbia
Ontario
Quebec
Recall class
Type II
Identification number
RA-74270